Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verastem Inc VSTM

Healthcare Biotechnology
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced... see more

Recent & Breaking News (NDAQ:VSTM)

Verastem to Host Conference Call on March 3rd to Discuss Fourth Quarter and Full-Year 2015 Financial Results and Recent Highlights

Business Wire March 1, 2016

Verastem to Present at Upcoming Investor Conferences

Business Wire January 27, 2016

Verastem to Present Scientific Data Supporting FAK Inhibition in Combination with Immune Checkpoint Inhibitors at Immunotherapy World 2016

Business Wire January 21, 2016

Washington University in St. Louis Initiates Clinical Study of Verastem's VS-6063 in Combination with Merck's Pembrolizumab and Gemcitabine in Pancreatic Cancer

Business Wire January 6, 2016

Verastem Reports Third Quarter 2015 Financial and Corporate Results

Business Wire November 9, 2015

Verastem to Present Preclinical Data at SITC 2015

Business Wire November 4, 2015

Verastem to Present Preclinical Data at the 2015 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

Business Wire October 27, 2015

Verastem Announces Reduction of Workforce

Business Wire October 8, 2015

Verastem Stops Enrollment Due to Futility in the COMMAND Study of VS-6063 for the Treatment of Malignant Pleural Mesothelioma

Business Wire September 28, 2015

Verastem Announces New Research Published in the Journal Cell That Highlights the Potential of FAK Inhibition to Enhance the Efficacy of Anti-Tumor Immunotherapy

Business Wire September 24, 2015

Verastem to Present Preclinical Data at ESMO/ECCO 2015

Business Wire September 17, 2015

Verastem Presents Clinical and Preclinical Data at the 16th World Conference on Lung Cancer

Business Wire September 10, 2015

Verastem to Present at Rodman and Renshaw 17th Annual Global Investment Conference

Business Wire September 3, 2015

Verastem Issues Statement Regarding WCLC Presentations

Business Wire August 26, 2015

Verastem to Present Data at the 16th World Conference on Lung Cancer

Business Wire August 26, 2015

Verastem Reports Second Quarter 2015 Financial and Corporate Results

Business Wire August 10, 2015

Verastem to Present at Cantor Fitzgerald's Inaugural Health Care Conference

Business Wire July 2, 2015

Verastem to Present at 2015 JMP Securities Life Sciences Conference

Business Wire June 17, 2015

Verastem Announces Executive Management Changes

Business Wire June 10, 2015

Verastem to Present at Jefferies 2015 Healthcare Conference

Business Wire May 27, 2015